sb 202190 has been researched along with Blood Pressure, High in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Touyz, RM | 1 |
| He, G | 1 |
| El Mabrouk, M | 1 |
| Diep, Q | 1 |
| Mardigyan, V | 1 |
| Schiffrin, EL | 1 |
1 other study available for sb 202190 and Blood Pressure, High
| Article | Year |
|---|---|
Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Hypertension; Imidazoles; | 2001 |